止血材市場：タイプ、製剤、用途別-2025～2030年の世界予測

止血材市場は、2023年に32億3,000万米ドルと評価され、2024年には34億2,000万米ドルに達すると予測され、CAGR 5.65%で成長し、2030年には47億5,000万米ドルに達すると予測されています。

止血材の範囲と定義は、血液の凝固を促進することで、外科手術や外傷の場面で出血を止めるために利用される医療機器や物質に関するものです。止血材は、特に心臓血管外科、外傷治療、ある種の臓器移植において、患者の回復時間や治療成績を向上させるために、選択的外科手術と緊急外科手術の両方で不可欠です。最終用途は、病院、外来手術センター、専門クリニックに及び、世界的に軍や外傷センターでの需要が増加しています。市場洞察によると、止血材市場は、特に新興国における医療インフラの進歩と相まって、外科手術の増加によって主に牽引されています。生分解性止血材や低侵襲手術に適した製品の開発などの技術革新は、企業が提供する製品を拡大する潜在的な機会を提供しています。主要成長要因としては、人口の高齢化、外科的介入を必要とする慢性疾患の増加、発展途上地域における医療支出の増加などが挙げられます。しかし、厳しい規制要件、潜在的な副作用、先進的止血製品の高価格など、実質的な制約は依然として残っており、市場成長の妨げとなる可能性があります。さらに、代替の創傷ケア製品や止血材製品との競合が市場拡大に悪影響を及ぼす可能性もあります。技術革新のための最良のセグメントとしては、生体適合性を高め、より速く作用し、副作用の少ない次世代型止血材の開発、新しい手術手技における止血材の使用を探求する研究への投資が挙げられます。さらに、持続可能で費用対効果の高いソリューションを生み出すことで、低リソース環境でのアクセスを拡大し、未開拓の市場可能性を提供することができます。市場競争は激しいため、一歩先を行くには研究機関との戦略的提携や協力が必要です。結論として、有望な機会があふれている一方で、企業は規制状況を乗り切り、研究開発に投資して課題に対処し、成長機会を効果的につかむ必要があります。

市場力学：急速に進化する止血材市場の主要市場洞察を公開

止血材市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 外科的介入の必要性が高まる慢性疾患の有病率
  • 低侵襲手術への志向の高まり
• 市場抑制要因
  • 製品リコールの増加
• 市場機会
  • バイオポリマーベースの使い捨ての台頭止血材
  • ナノ技術の統合による、より効率的で的を絞った止血材
• 市場課題
  • 止血材ツールや試薬の使用に伴う感染や交差汚染のリスク

ポーターのファイブフォース：止血材市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、止血材市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：止血材市場における外部からの影響の把握

外部マクロ環境要因は、止血材市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：止血材市場における競合情勢の把握

止血材市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：止血材市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、止血材市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：止血材市場における成功への道筋を描く

止血材市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 外科的介入の必要性が高まっている慢性疾患の蔓延
    • 低侵襲手術への傾向の高まり
  • 抑制要因
    • 製品リコールの発生件数の増加
  • 機会
    • バイオポリマーベースの使い捨ての台頭止血材
    • ナノ技術の統合により、より効率的で対象を絞った止血材を作成
  • 課題
    • 止血材ツールと試薬の使用に伴う感染と交差汚染のリスク
• 市場セグメンテーション分析
  • タイプ：出血を最小限に抑える効果の向上により、組み合わせ止血材の使用を拡大
  • 製剤：外科的介入中の出血を抑制と予防するための粉末止血材の成長可能性
  • 用途：心臓血管手術における失血防止と手術成功の保証における止血材の重要な役割
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 止血材市場：タイプ別

• イントロダクション
• コラーゲンベース止血材
• 混合止血材
• ゼラチンベース止血材
• 酸化再生セルロースベース止血材
• トロンビンベース止血材

第7章 止血材市場：製剤別

• イントロダクション
• マトリックス＆ジェル
• 粉末
• シート＆パッド
• スポンジ

第8章 止血材市場：用途別

• イントロダクション
• 心臓血管外科
• 一般外科
• 婦人科手術
• 神経外科
• 整形外科
• 再建手術

第9章 南北アメリカの止血材市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の止血材市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの止血材市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Teleflex、心臓外科手術におけるQuikClot Control+止血デバイスの使用拡大についてFDAの承認を取得
  • Baxter、吸収性止血粉末「PERCLOT」を発売
  • Artivion、PerClotのFDA承認を取得、バクスターへの移管を開始
  • Olympus Europa SE & Co. KGがEndoclotとの提携を拡大し、止血材を発売
  • Darling Ingredients、ブラジルのゼラチン・コラーゲン製造会社Gelnexの買収を完了
  • 重度の手術出血を抑えるキトサンベースの止血材がFDAの認可を取得
  • Advamedica Inc、Ax-Surgi外科用止血材のFDA認可を発表
  • Medcura、LifeGel吸収性外科用止血材で画期的デバイス指定を取得
  • Medtronic plcのネックスパスダー末内視鏡止血システムが米国FDAの認可を取得
  • Hemostasis LLC、Fiagon Medical Technologiesの買収を完了
• 戦略分析と提言

企業一覧

• A.R. Medicom, Inc.
• ACTEON Group
• Advamedica Inc.
• Advanced Medical Solutions Group PLC
• Advin Health Care
• Aegis Lifesciences Private Limited
• Argon Medical Devices
• B. Braun SE
• Baxter International Inc.
• Becton, Dickinson and Company
• Betatech Medical
• Convatec Group PLC
• Cook Group Incorporated
• Cortis Medtech Pvt Ltd
• Cotran Corporation
• Dolphin Sutures by Futura Surgicare Pvt. Ltd.
• Dynarex Corporation
• Gelita AG
• Hangzhou Singclean Medical Products Co.,Ltd.
• Healthium Medtech Ltd
• Hemostasis, LLC
• Integra LifeSciences Holdings Corporation
• Johnson & Johnson Services, Inc.
• Medcura, Inc.
• Medline Industries, LP
• Medprin BIoTech GmbH
• Medtronic PLC
• Meril Life Sciences Pvt. Ltd.
• Olympus Corporation
• Pfizer Inc.
• Rousselot BV by Darling Ingredients International Holding B.V.
• Royal DSM
• Shilpa Medicare Limited
• Stapleline Medizintechnik GmbH
• Stryker Corporation
• SYMATESE
• Teleflex Incorporated
• Terumo Corporation
• Zhejiang Perfectseal New Material Technology Co., Ltd.
• Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

• FIGURE 1. HEMOSTATS MARKET RESEARCH PROCESS
• FIGURE 2. HEMOSTATS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEMOSTATS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEMOSTATS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HEMOSTATS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HEMOSTATS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HEMOSTATS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HEMOSTATS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HEMOSTATS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HEMOSTATS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HEMOSTATS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HEMOSTATS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HEMOSTATS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HEMOSTATS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HEMOSTATS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HEMOSTATS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HEMOSTATS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HEMOSTATS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HEMOSTATS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEMOSTATS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEMOSTATS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HEMOSTATS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HEMOSTATS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HEMOSTATS MARKET DYNAMICS
• TABLE 7. GLOBAL HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HEMOSTATS MARKET SIZE, BY COLLAGEN-BASED HEMOSTATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HEMOSTATS MARKET SIZE, BY COMBINATION HEMOSTATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HEMOSTATS MARKET SIZE, BY GELATIN-BASED HEMOSTATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HEMOSTATS MARKET SIZE, BY OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HEMOSTATS MARKET SIZE, BY THROMBIN-BASED HEMOSTATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HEMOSTATS MARKET SIZE, BY MATRIX & GEL HEMOSTATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HEMOSTATS MARKET SIZE, BY POWDER HEMOSTATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HEMOSTATS MARKET SIZE, BY SHEET & PAD HEMOSTATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HEMOSTATS MARKET SIZE, BY SPONGE HEMOSTATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HEMOSTATS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HEMOSTATS MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HEMOSTATS MARKET SIZE, BY GYNECOLOGICAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HEMOSTATS MARKET SIZE, BY NEUROLOGICAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL HEMOSTATS MARKET SIZE, BY ORTHOPEDIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL HEMOSTATS MARKET SIZE, BY RECONSTRUCTIVE SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS HEMOSTATS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. CANADA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES HEMOSTATS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC HEMOSTATS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. CHINA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. CHINA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 54. CHINA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDIA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. INDIA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 57. INDIA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. ITALY HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ITALY HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 109. ITALY HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. POLAND HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. POLAND HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 121. POLAND HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. QATAR HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. QATAR HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 124. QATAR HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM HEMOSTATS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM HEMOSTATS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM HEMOSTATS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. HEMOSTATS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 153. HEMOSTATS MARKET, FPNV POSITIONING MATRIX, 2023

The Hemostats Market was valued at USD 3.23 billion in 2023, expected to reach USD 3.42 billion in 2024, and is projected to grow at a CAGR of 5.65%, to USD 4.75 billion by 2030.

The scope and definition of hemostats pertain to medical devices or substances utilized to arrest bleeding in surgical and trauma scenarios by promoting the coagulation of blood. Hemostats are essential in both elective and emergency surgical procedures to enhance patient recovery times and outcomes, particularly in cardiovascular surgery, trauma care, and certain types of organ transplants. The end-use scope extends across hospitals, ambulatory surgical centers, and specialty clinics, with an increasing demand observed in military and trauma centers globally. Market insights reveal that the hemostats market is predominantly driven by a rise in surgical procedures, coupled with advancements in healthcare infrastructure, particularly in emerging economies. Technological innovations, such as the development of biodegradable hemostats and products suited for minimally invasive procedures, offer potential opportunities for businesses to expand their offerings. Key growth factors include an aging population, a rise in chronic conditions that necessitate surgical intervention, and increased healthcare spending across developing regions. However, substantial limitations persist, including stringent regulatory requirements, potential side effects, and the high cost of advanced hemostatic products, which may hinder market growth. Additionally, competition from alternative wound care and blood styptic products can negatively impact market expansion. The best areas for innovation include the development of next-generation hemostats with enhanced biocompatibility, faster action, and fewer adverse effects, as well as investment in research exploring the use of hemostats in novel surgical techniques. Additionally, creating sustainable, cost-effective solutions can broaden access in low-resource settings, providing untapped market potential. The competitive nature of the market demands strategic partnerships and collaborations with research institutions to stay ahead. In conclusion, while promising opportunities abound, companies must navigate regulatory landscapes and invest in R&D to address challenges and seize growth prospects effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemostats Market

The Hemostats Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of chronic disorders with increasing need for surgical interventions
  • Growing inclination toward minimally invasive surgeries
• Market Restraints
  • Rising incidences of product recalls
• Market Opportunities
  • Rise of biopolymer-based disposable hemostats
  • Integration of nanotechnology to create more efficient and targeted hemostats
• Market Challenges
  • Risk of infection and cross contamination associated with the use of hemostats tools and reagents

Porter's Five Forces: A Strategic Tool for Navigating the Hemostats Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemostats Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemostats Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemostats Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemostats Market

A detailed market share analysis in the Hemostats Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemostats Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemostats Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemostats Market

A strategic analysis of the Hemostats Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemostats Market, highlighting leading vendors and their innovative profiles. These include A.R. Medicom, Inc., ACTEON Group, Advamedica Inc., Advanced Medical Solutions Group PLC, Advin Health Care, Aegis Lifesciences Private Limited, Argon Medical Devices, B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Betatech Medical, Convatec Group PLC, Cook Group Incorporated, Cortis Medtech Pvt Ltd, Cotran Corporation, Dolphin Sutures by Futura Surgicare Pvt. Ltd., Dynarex Corporation, Gelita AG, Hangzhou Singclean Medical Products Co.,Ltd., Healthium Medtech Ltd, Hemostasis, LLC, Integra LifeSciences Holdings Corporation, Johnson & Johnson Services, Inc., Medcura, Inc., Medline Industries, LP, Medprin Biotech GmbH, Medtronic PLC, Meril Life Sciences Pvt. Ltd., Olympus Corporation, Pfizer Inc., Rousselot BV by Darling Ingredients International Holding B.V., Royal DSM, Shilpa Medicare Limited, Stapleline Medizintechnik GmbH, Stryker Corporation, SYMATESE, Teleflex Incorporated, Terumo Corporation, Zhejiang Perfectseal New Material Technology Co., Ltd., and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Hemostats Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Collagen-Based Hemostats, Combination Hemostats, Gelatin-Based Hemostats, Oxidized Regenerated Cellulose-Based Hemostats, and Thrombin-Based Hemostats.
• Based on Formulation, market is studied across Matrix & Gel Hemostats, Powder Hemostats, Sheet & Pad Hemostats, and Sponge Hemostats.
• Based on Application, market is studied across Cardiovascular Surgery, General Surgery, Gynecological Surgery, Neurological Surgery, Orthopedic Surgery, and Reconstructive Surgery.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic disorders with increasing need for surgical interventions
    • 5.1.1.2. Growing inclination toward minimally invasive surgeries
  • 5.1.2. Restraints
    • 5.1.2.1. Rising incidences of product recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Rise of biopolymer-based disposable hemostats
    • 5.1.3.2. Integration of nanotechnology to create more efficient and targeted hemostats
  • 5.1.4. Challenges
    • 5.1.4.1. Risk of infection and cross contamination associated with the use of hemostats tools and reagents
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Expanding the use of combination hemostats owing to their enhanced effectiveness in minimizing bleeding
  • 5.2.2. Formulation: Growing potential of powder hemostats for controlling and preventing bleeding during surgical intervention
  • 5.2.3. Application: Significant role of hemostats in cardiovascular surgeries to prevent blood loss and ensure successful outcomes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hemostats Market, by Type

• 6.1. Introduction
• 6.2. Collagen-Based Hemostats
• 6.3. Combination Hemostats
• 6.4. Gelatin-Based Hemostats
• 6.5. Oxidized Regenerated Cellulose-Based Hemostats
• 6.6. Thrombin-Based Hemostats

7. Hemostats Market, by Formulation

• 7.1. Introduction
• 7.2. Matrix & Gel Hemostats
• 7.3. Powder Hemostats
• 7.4. Sheet & Pad Hemostats
• 7.5. Sponge Hemostats

8. Hemostats Market, by Application

• 8.1. Introduction
• 8.2. Cardiovascular Surgery
• 8.3. General Surgery
• 8.4. Gynecological Surgery
• 8.5. Neurological Surgery
• 8.6. Orthopedic Surgery
• 8.7. Reconstructive Surgery

9. Americas Hemostats Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Hemostats Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Hemostats Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+ Hemostatic Device Usage in Cardiac Surgical Procedures
  • 12.3.2. Baxter Launches PERCLOT Absorbable Hemostatic Powder
  • 12.3.3. Artivion Gains FDA Approval for PerClot, Starts Transfer to Baxter
  • 12.3.4. Olympus Europa SE & Co. KG Expands Endoclot Partnership with Endoclot to Launch Hemostatic Agents
  • 12.3.5. Darling Ingredients Completes Acquisition of Brazilian Gelatin and Collagen Producer Gelnex
  • 12.3.6. Chitosan-Based Hemostat For Controlling Severe Surgical Bleeding Gets FDA Clearance
  • 12.3.7. Advamedica Inc Announces FDA Clearance for Ax-Surgi Surgical Hemostat
  • 12.3.8. Medcura, Inc. Receives Breakthrough Device Designation for its LifeGel Absorbable Surgical Hemostat
  • 12.3.9. Medtronic plc Nexpowder Endoscopic Hemostasis System Receives U.S. FDA Clearance
  • 12.3.10. Hemostasis LLC Closes Acquisition of Fiagon Medical Technologies
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. A.R. Medicom, Inc.
• 2. ACTEON Group
• 3. Advamedica Inc.
• 4. Advanced Medical Solutions Group PLC
• 5. Advin Health Care
• 6. Aegis Lifesciences Private Limited
• 7. Argon Medical Devices
• 8. B. Braun SE
• 9. Baxter International Inc.
• 10. Becton, Dickinson and Company
• 11. Betatech Medical
• 12. Convatec Group PLC
• 13. Cook Group Incorporated
• 14. Cortis Medtech Pvt Ltd
• 15. Cotran Corporation
• 16. Dolphin Sutures by Futura Surgicare Pvt. Ltd.
• 17. Dynarex Corporation
• 18. Gelita AG
• 19. Hangzhou Singclean Medical Products Co.,Ltd.
• 20. Healthium Medtech Ltd
• 21. Hemostasis, LLC
• 22. Integra LifeSciences Holdings Corporation
• 23. Johnson & Johnson Services, Inc.
• 24. Medcura, Inc.
• 25. Medline Industries, LP
• 26. Medprin Biotech GmbH
• 27. Medtronic PLC
• 28. Meril Life Sciences Pvt. Ltd.
• 29. Olympus Corporation
• 30. Pfizer Inc.
• 31. Rousselot BV by Darling Ingredients International Holding B.V.
• 32. Royal DSM
• 33. Shilpa Medicare Limited
• 34. Stapleline Medizintechnik GmbH
• 35. Stryker Corporation
• 36. SYMATESE
• 37. Teleflex Incorporated
• 38. Terumo Corporation
• 39. Zhejiang Perfectseal New Material Technology Co., Ltd.
• 40. Zimmer Biomet Holdings, Inc.